Pharma giants AstraZeneca, Bayer, and Boehringer Ingelheim have revealed plans to invest hundreds of millions of dollars in Mexico, defying trade tensions between Mexico and the United States. The companies, along with Mexico’s Carnot Laboratories, are collectively injecting $600 million into their Mexican operations, showcasing a significant commitment to the Mexican market. This move comes as Mexico works to avoid a 30% tariff on many exports to the US, a measure that was temporarily delayed by 90 days. President Trump’s threats of imposing high tariffs on imported drugs have also added pressure to the pharmaceutical industry.
Mexican President Claudia Sheinbaum expressed that these new investments in the pharmaceutical sector are aligned with her vision to boost local manufacturing substantially, aiming to reduce reliance on imports from Chinese firms accused of exploiting Mexico as a gateway into the US. Bayer, committing $160 million over the next five years, plans to expand its production facilities in Mexico, the largest economy in Latin America. Boehringer Ingelheim is embarking on a multi-year investment of $187 million to revamp its tablet production plant in Xochimilco, intending to make it the largest globally. AstraZeneca, on its part, will allocate $120.7 million until 2026 to enhance clinical research operations and expand manufacturing facilities catering to various health conditions like type 2 diabetes and chronic kidney disease.
Carnot Laboratories announced a $187 million investment over five years for a new plant in Hidalgo, underscoring the industry’s collective confidence in Mexico’s pharmaceutical landscape. Despite the existing trade tensions, Mexico benefits from the USMCA free trade agreement, enabling tariff-free access for nearly 85% of its exports to the US. However, Trump’s imposition of tariffs on sectors like automotive, steel, and aluminum continues to pose challenges. Notwithstanding these hurdles, companies like Heineken, Walmart, and Netflix have also recently unveiled substantial investments in Mexico, showcasing ongoing confidence in the country’s business environment.
Key Takeaways:
– AstraZeneca, Bayer, and Boehringer Ingelheim commit $600 million to Mexican operations, despite US-Mexico trade tensions.
– Mexico aims to bolster local manufacturing through pharmaceutical investments, reducing dependence on Chinese imports.
– Trump’s tariff threats on pharmaceuticals intensify industry concerns, prompting substantial investments to strengthen Mexico’s pharmaceutical sector.
– Continued investments from multinational companies like Heineken, Walmart, and Netflix demonstrate sustained interest in Mexico’s business landscape despite trade challenges.
Read more on thepeninsulaqatar.com